Home Blog Page 1720

/C O R R E C T I O N — The Genovation Foundation/

By
Advertorial Desk
-

In the news release, Dr James Liang Launches HK$500 Million “Genovation Foundation” to Address Low Fertility, issued 20-Nov-2025 by The Genovation Foundation over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows:

Dr James Liang Launches HK$500 Million “Genovation Foundation” to Address Low Fertility

HONG KONG, Nov. 20, 2025 /PRNewswire/ — On World Children’s Day, Dr James Liang, Co-founder of Trip.com Group, announced the establishment of the Genovation Foundation Limited in Hong Kong. Established in his personal capacity, the foundation pledges HK$500 million over five years to address declining fertility through three key avenues: economic subsidies, cultural advocacy, and policy research.

The name Genovation combines “Gene” and “Innovation”, symbolising both the continuity of life and the pursuit of creative solutions to pressing social challenges. This marks another significant step in Liang’s decade-long dedicated research into demographic issues, moving from corporate practice into the realm of public philanthropy.

Supporting Policy Research and Global Dialogue

Beyond funding policy research, including the Global Fertility Crisis Forum scheduled to launch in January 2026 and held annually thereafter, the foundation has opened applications in two further areas:

  • Childbearing subsidies for PhD students in Hong Kong
  • Grants for fertility-friendly cultural and artistic projects worldwide

As a scholar-entrepreneur who has long studied the relationship between demographics and innovation, Liang has repeatedly warned that a shrinking younger population will erode national creativity and long-term economic vitality. He argues that addressing this challenge requires coordinated action across government, business, and society. By piloting initiatives in Hong Kong and focusing on three strategic directions, the foundation aims to create replicable models for wider adoption.

Financial Support for Doctoral Students

In its first phase, the foundation will pilot a targeted subsidy for doctoral students at higher education institutions in Hong Kong. As a crucial reserve of future research talent, PhD students often face multiple pressures of academic advancement, early career development, and family planning. Despite being in their prime reproductive years, many are forced to delay or abandon parenthood due to research demands, limited income, and the high cost of childcare.

To address this, the foundation will provide a HK$50,000 childcare and education grant to families of full-time PhD students based in Hong Kong whose children are born on or after 1 January 2026. Applications require a birth certificate, proof of enrolment, and academic transcripts. The foundation pledges to complete reviews within 14 working days and disburse funds within five working days. (Further details are available at http://www.genovationfoundation.org/ )

Promoting Fertility-Friendly Cultural Innovation

Liang recognises that low fertility is not only an economic issue but also shaped by social attitudes and cultural anxieties. To foster a supportive environment, the foundation has established a Fertility-Friendly Cultural Innovation Project, inviting global submissions of creative works that inspire childbearing, convey family warmth, and reduce anxiety around parenthood.

The foundation provides grants of up to HK$1 million to individuals and organisations, awarded annually to support creative works — from film and literature to art installations — that celebrate the joy of family life and the positive impact of childbearing.”

Global Fertility Crisis Forum

Low fertility is a shared global challenge requiring international collaboration. A flagship initiative of the foundation will be the Global Fertility Crisis Forum, to be held in Hong Kong in January 2026. Co-hosted by leading institutions including Peking University and the University of Hong Kong, the forum will examine demographic trends, the economic impact of declining fertility, policy responses, and the balance between women’s reproductive choices and career development.

Combining macro-level analysis with personal sharing, the forum is intended to become a regular platform for international dialogue, pooling global expertise to inform policy-making. Liang believes that evidence-based policies and sufficient support can meaningfully raise fertility intentions, and the forum will serve as a hub for such collaborative efforts.

More information about the Global Fertility Crisis Forum can be found at https://globalfertilitycrisis.org/

From Corporate Practice to Public Philanthropy

The creation of the Genovation Foundation represents another breakthrough in Liang’s long-standing commitment to fertility support. Over the past decade, he has authored works such as The Demographics of Innovation and Population Strategies: How Population Affects Economy and Innovation, while also implementing childcare-friendly measures at Trip.com Group, including subsidies for employees worldwide and three additional days of parental leave.

He has sought to build public consensus through creative initiatives, such as the philosophical novel and play After Immortality and the interview series James Liang in Dialogue with Multi-Child Families. Liang has consistently called for stronger national support, including tax relief, mortgage interest rebates for larger families, and expanded childcare provision.

With government subsidies now in place and public awareness of the fertility crisis growing, Liang’s personal investment of HK$500 million reflects his philosophy of “testing solutions through corporate practice, expanding impact through public philanthropy”. From supporting employees to engaging society at large, and from financial subsidies to a combined framework of economic, cultural, and policy support, Liang emphasises that safeguarding fertility intentions is safeguarding the future of society and the foundations of innovation. He hopes the Genovation Foundation will act as a seed, encouraging wider participation and transforming childbearing from a “dilemma” into a “choice of hope and happiness”.

About the Genovation Foundation

The Genovation Foundation is a philanthropic organisation dedicated to population development and social innovation. The name Genovation combines “Gene” and “Innovation”, symbolising both the continuity of life and the pursuit of creative solutions to pressing social challenges. Established in Hong Kong by Dr James Liang in his personal capacity, the foundation will invest HK$500 million over five years, committed to alleviating poverty through education, promoting fertility, and advocating family virtues.

Official website: http://www.genovationfoundation.org/

 media contact: info@genovationfoundation.org

CHANGAN Q05’s Debut Attracts Global Attention to Changan’s Intelligent EV Lineup

By
Advertorial Desk
-

GUANGZHOU, CHINA – Media OutReach Newswire – 24 November 2025 – Changan unveiled the all-new CHANGAN Q05 on Friday at the 2025 Guangzhou International Automobile Exhibition, announcing official pricing and hosting the first owner delivery ceremony—an event that quickly became a highlight for both media and visitors. Alongside the Q05, Changan DEEPAL and AVATR showcased their flagship models, reinforcing China’s growing leadership in intelligent electric vehicles.

Designed by an international team of 915 members from 31 countries and regions led by Klaus Zyciora, The CHANGAN Q05 embodies an “Inspired by light” design concept. The model adopts a “golden dimensional ratio” that balances agility and spaciousness, featuring a width-to-height ratio of 0.86 and an axle-to-length ratio of 0.62.

Built on Changan’s independently developed SDA digital-intelligence platform -the only Ethernet Ring Network Architecture globally aside from Tesla Cybertruck-the Q05 focuses on four core strengths, comfort, space, real-world range, and intelligent features. Offering a new experience for young families and urban professionals.

In terms of comfort, CHANGAN Q05 features massaging, ventilation, and heating functions for both front seats, along with skin-friendly and eco-friendly interior materials, offering a comprehensive comfortable experience.

With an optimized interior layout achieving an 86.6 percent space utilization rate, the Q05 provides a spacious cabin that maximizes every usable inch, delivering both comfort and generous practicality.

‌For range‌, the Golden Shield 2.0 3C fast-charging battery enables a quick 15-minute charge, ensuring hassle-free driving for both city commutes and long trips. On intelligence, the car is equipped with SDA Pilot and SDA AI OS, featuring a lidar system and an auxiliary driving blue light, making driving more intuitive and user-friendly. More details will be announced closer to the market launch.

Meanwhile, at the AVATR booth, models like the AVATR 12 and AVATR 06 showcased the brand’s ‌”Emotive Luxury”‌ design philosophy. At the Exhibition, Changan Deepal also presented a total of six products. Among them, Deepal S05 and Deepal S07 have already been exported to nearly 100 countries and regions across five continents worldwide.

Currently, Changan Automobile is accelerating its global layout, establishing a presence in five key regions. The company is building a global smart mobility ecosystem, further strengthened by the recent establishment of China Changan Automobile Group on July 29th. Focusing on electrification and intelligence as core strengths, Changan aims to deliver greener, smarter, and more comfortable vehicles to global customers.

Hashtag: #Changan

The issuer is solely responsible for the content of this announcement.

CKGSB Celebrates 23rd Anniversary with Unveiling of First Permanent Beijing Campus

By
Advertorial Desk
-

BEIJING, Nov. 24, 2025 /PRNewswire/ — Cheung Kong Graduate School of Business (CKGSB) celebrates its 23rd anniversary with the unveiling of its first permanent Beijing campus. For the first time since its founding on November 21, 2002, the school will have a permanent home — a space that represents its identity as an innovative management education hub and its commitment to redefining business education in the long run. The new campus will officially open in 2026.

Cheung Kong Graduate School of Business's First Permanent Beijing Campus
Cheung Kong Graduate School of Business’s First Permanent Beijing Campus

A Milestone in Growth and Influence

Since its inception, CKGSB has grown into one of China’s most influential business schools. Today, its network of 24,500 alumni includes many of the country’s leading entrepreneurs and executives — individuals who collectively guide one fifth of China’s most valuable brands. Known for their global outlook, innovative thinking, and commitment to social responsibility, CKGSB alumni exemplify the school’s values in action.

The new campus is a physical expression of this evolution. Located in central Beijing’s Ciqikou — interpreted by the school’s dean as a “China Gateway” — CKGSB offers a deep understanding and strategic connectivity to China’s business from the inside.  

A Campus Designed with Purpose

Spanning a building area of 30,000 square meters with a distinctive façade reminiscent of a vessel setting sail, the campus underscores CKGSB’s ambition to break new ground in business education and become a new-generation global business school.

Inside, the campus brings together classrooms, learning spaces, a conference center, faculty offices, areas for alumni gatherings, and digital-platform facilities, creating an integrated hub open to students, alumni, and visiting global leaders. Open, light-filled rooms, interconnected courtyards, and transparent structures foster collaboration and exchange, reinforcing CKGSB’s belief in openness and shared progress.

A Symbol of Continuity and Renewal

On its anniversary, CKGSB reaffirms that education extends beyond knowledge transmission. It is about cultivating empathy, foresight, and responsible leadership. The new campus reflects the collective support of CKGSB’s community, including alumni and students who made donations to turn a long-held dream into reality.

As CKGSB prepares to move into its new home in 2026, the school sees this moment as both a culmination of its first 23 formative years and the beginning of a new chapter. Going forward, the school aspires to become a globally connected, socially conscious, and future-focused world-class institution.

Clarivate Launches Derwent Patent Monitor to Enable Fast and Accurate Decision-making with AI

By
Advertorial Desk
-

New enterprise solution streamlines IP and R&D patent reviews and accelerates freedom to operate, patentability, and infringement related decisions

LONDON, Nov. 24, 2025 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Derwent Patent Monitor to streamline intellectual property (IP) and research and development (R&D) collaborative patent reviews when determining patentability, assessing freedom to operate (FTO) and evaluating opposition or assertion. Built with proprietary data, Derwent Patent Monitor offers AI-powered evaluation of potential threats helping to accelerate first-pass reviews (Threat Analysis) to surface the most critical risks for stakeholders. This feature empowers patent professionals to proceed quickly and with higher confidence.

Shandon Quinn, Vice President, Patent Intelligence, Clarivate, said: “One of the biggest challenges IP leaders mention to me is upgrading their team’s partnership with R&D for filing stronger patents and minimizing infringement risk.  Yet too often the process is slowed down by siloed teams and disjointed tools and processes. Derwent Patent Monitor is the first tool of its kind to bring together flexible collaboration and review workflows, unique Derwent patent data and AI technology to help teams quickly identify potential risks and accelerate critical IP decisions for FTO, opposition and patent filing.”

The new software is built on proprietary data from the Derwent World Patents Index (DWPI), the world’s most comprehensive database of 67m+ invention summaries written by 850+ Clarivate subject matter experts to help collaborators save time when reviewing patents of interest.

Purpose-built for collaboration, Derwent Patent Monitor helps patent teams save time and boost efficiency through structured, project-based reviews and real-time feedback – eliminating the need for scattered emails and spreadsheets. Teams become more aligned and informed on key reviews, enabling a faster, more connected patent monitoring process.

To learn more, please visit Derwent Patent Monitor.

About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media contact:
Sofia Nogués, Sr. External Communications Manager
newsroom@clarivate.com

 

Developers in Southeast Asia and India are teaching themselves AI, according to new Agoda report

By
Advertorial Desk
-

Self-directed upskilling is accelerating innovation but exposing gaps across markets

SINGAPORE, Nov. 24, 2025 /PRNewswire/ — New findings from Agoda’s AI Developer Report 2025 reveal that developers are teaching themselves AI faster than many companies can roll out AI training, fueling rapid skill growth across the region but exposing gaps in access, support, and structure.

AI developer report
AI developer report

AI is now a defining force in career growth and learning. Eighty-seven percent of developers have changed their learning or career priorities because of AI, and 62% believe it will create more opportunities than it replaces. Most are advancing on their own: 72% of developers are self-taught, while only 28% receive employer-led training.

As formal programs struggle to keep pace, peer learning has become a key pillar of AI education. More than half (52%) turn to online communities or open-source projects as their main learning platforms, driving a fast-moving culture of experimentation, collaboration, and shared growth.

However, this momentum is not evenly distributed. Developers in Singapore are nearly twice as likely as those in Vietnam to have access to formal AI training, and a 25-point confidence gap between senior and junior engineers shows how mentorship and structure can accelerate skill development and close experience gaps.

The fast pace of technological change also brings new pressure. 44% of developers worry about falling behind as AI evolves, while 58% now view AI proficiency as a baseline hiring requirement. The result is a workforce that is ambitious, adaptable, and learning faster than organizations can teach, but also uneven and under strain.

“Developers across the region view AI as a tool to accelerate their work, not a replacement for judgment and they’re upskilling themselves faster than many organizations can respond,” said Idan Zalzberg, Chief Technology Officer at Agoda. “This self-driven momentum is a powerful strength, but to sustain it, companies must build systems of trust and accountability around them”

Agoda has invested in building these systems through programs that support both its engineering community and the broader tech ecosystem. The company runs internal AI hackathons where engineers experiment with emerging technologies, hosts regular tech talks and knowledge-sharing sessions to accelerate peer learning, and operates Tech Camp Day, a tech-focused social impact program that has empowered thousands of university and high school students across Thailand with essential skills. These initiatives reflect Agoda’s commitment to upskilling local tech talent, fostering innovation, and investing in the communities where it operates.

The Agoda AI Developer Report 2025 draws on extensive input from developers across Southeast Asia and India, along with insights from leading regional companies such as Carousell, MoMo, Omise, and SCB 10x. It provides a comprehensive view of how AI is being adopted, integrated, and experienced across the region’s developer ecosystem.

For more information and to download the free report, visit APAC developer report.

Uni-Bio Science Group Embarks on New Strategy and Launches New Website, Advancing Towards Becoming a Global Leader in Regenerative Medicine

By
Advertorial Desk
-

HONG KONG SAR – EQS Newswire – 24 November 2025 – Uni-Bio Science Group Limited (“Uni-Bio” or “the Group”) recently announced its official entry into a new phase of strategic development. Over the past few years, amidst profound biopharmaceutical industry transformation and multiple market challenges, the Group has consistently adhered to stable operations as its core focus, building financial resilience and commercialization capabilities. It has not only achieved sustained revenue growth and healthy cash flow, but also successfully advanced its blockbuster product – Bogutai® (Teriparatide Injection) – which was approved in China in January 2024, filling a crucial gap in its osteoporosis treatment portfolio. The Group is currently actively advancing the US FDA application for Uni-PTH, expected to be approved in 2027, and has entered a strategic collaboration with Kexing for six international markets, marking a key step in its global strategy.

Building on these solid achievements, Uni-Bio has decided to shift its strategic focus comprehensively from “Stable Growth” to “Innovation-Driven.” Leveraging next-generation synthetic biology and complex peptides as technological engines and focusing on the forefront of regenerative medicine, the Group is initiating a strategic leap from an “Excellent Pharmaceutical Company” to a “Global Leader in Regenerative Medicine.”

1. New Corporate Vision and Mission: Anchoring the Future of Regenerative Medicine

Alongside this strategic upgrade, Uni-Bio announced its new corporate vision and mission, demonstrating not only its ambition to be rooted in China with a global outlook but also its deep consideration for the future of human health.

Vision:
” To Be the Global Leader in Regenerative Medicine, Redefining How Science Restores and Extends Human Life.”

Mission:
“Powering the Advancement of Regenerative Medicine with Next-Generation Synthetic Biology and Complex Peptide Innovation.”

2. Strategic Focus Areas: Comprehensive Breakthroughs in Four Regenerative Medicine Fields

Capitalizing on its profound expertise in synthetic biology and peptide technology, Uni-Bio is building a transformative pipeline covering four key areas – Muscular-Skeletal Regeneration, Skin Regeneration, Ocular Regeneration, and ENT (Ear, Nose, and Throat) Regeneration. These areas address core unmet clinical needs and promote the transition of regenerative medicine from the laboratory to broad clinical application through the deep integration of cutting-edge technologies.

(1) Muscular-Skeletal Regeneration

Focus on developing osteoporosis treatment and repair products, combined with stem cell technology, to drive breakthroughs in the diagnosis and treatment of bone, cartilage, and muscle injuries and degenerative diseases. Specific projects include:

  • UB107 (BMP-2 Biomedical Material): A key growth factor in regenerative medicine, BMP-2 can be widely used clinically for bone defect reconstruction and spinal fusion surgery. It is expected to be approved for market launch in 2028, further consolidating Uni-Bio’s market share and position in the field of bone regeneration.
  • UB106 (Novel Target Antibody for Obesity): Addressing the limitations of current obesity treatments, UB106 directly targets issues such as muscle loss, frequent dosing, gastrointestinal side effects, and pancreatitis. It is expected to be approved as early as 2030, offering a new treatment option for patients with obesity.

(2) Skin Regeneration

Leveraging advanced growth factor technologies and innovative delivery systems to provide precise repair solutions for burns, scalds, and hard-to-heal wounds, while also offering comprehensive solutions in the medical aesthetics field. Recently approved products include:

  • GeneTime® (Human Epidermal Growth Factor Derivative for External Use, Liquid, 30ml large specification): Approved by the NMPA in November 2025 (Approval No.: 國藥准字 S20258020). The approval of this new specification will significantly enhance GeneTime’s clinical applicability and market coverage, meeting the diverse medication needs of medical institutions at all levels and the end market.
  • Gene Queens® (Triple Protein Repair &Balance Ampoule): This product was approved recently, further completing the Group’s comprehensive “Drug & Medical Device & Cosmetic” skincare solution portfolio.

(3) Ocular Regeneration

Uni-Bio is actively exploring the field of ocular regeneration, utilizing advanced strategies such as hEGF and anti-VEGF, to remodel ocular surface and retinal function. Through active collaborations with leading international companies and top domestic universities, the Group is advancing the R&D of potential drugs for diseases, such as age-related macular degeneration. The Group’s mission is to accelerate the translation of cutting-edge technologies into clinical applications, thereby bringing new hope to patients with ocular diseases.

(4) ENT Regeneration

Centered on neurotrophic factor technology, Uni-Bio is pioneering innovative R&D in ENT regeneration, The Group is exploring novel solutions for reversing hearing loss and rebuilding olfactory function, driving new breakthroughs in the restoration of ENT organ function.

3. Reiterating the Firm Commitment to Innovation and Collaboration

Entering this new phase of strategic development, Uni-Bio is infusing the pioneering spirit of its startup days into a higher-level mission. This transformation marks the Group’s official evolution from a biopharmaceutical company with strong commercialization capabilities to a clinical-value-oriented leader in regenerative medicine driven by frontier science.

Consequently, Uni-Bio will more openly embrace collaboration across industry-academia-research-medicine, international technology partnerships, and co-building a capital ecosystem. It will actively seek deep synergies with top global research institutions, clinical experts, industry partners, and investors. To communicate this strategic vision and R&D progress more transparently and efficiently, Uni-Bio has simultaneously launched a new Chinese and English official website. The new website systematically presents the Company’s pipeline across the four regenerative medicine fields, its technology platforms, and milestone achievements, while also strengthening investor relations (IR) and scientific collaboration access points, aiming to become a vital bridge connecting global partners.

We sincerely invite partners, investors, research colleagues, and friends from all sectors interested in the future of regenerative medicine to visit Uni-Bio’s new website, delve deeper into our scientific story, and join us in participating and witnessing this journey of reshaping life through innovation.

Uni-Bio Chinese Website: https://www.uni-bioscience.com/
Uni-Bio English Website: https://www.uni-bioscience.com/enHashtag: #UniBioScienceGroup

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001(Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to becoming a global leader in regenerative medicine, redefining how science restores and extends human life.

ADB Approves USD 36 Million to Boost Skills, Employment for Lao Youth

By
Phontham Visapra
-
ADB Approves USD 36 Million to Boost Skills, Employment for Lao Youth
This image is used only for representational purpose (photo credit: Asian Development Bank)

The Asian Development Bank (ADB) has approved a USD 36 million financing package to strengthen technical and vocational education and training (TVET) in Laos, aiming to equip graduates with skills that meet current labor market needs and expand employment opportunities for young people, particularly women.

Continue

Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial

By
Advertorial Desk
-

Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models

SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ — Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has administered the first dose of its CK1α-selective degrader PIN-5018 in a Phase 1 clinical trial. The first patient enrolled has adenoid cystic carcinoma (ACC), a rare malignancy with limited treatment options.

PIN-5018 is an oral CK1α degrader developed based on the novel hypothesis of “synthetic activation of p53.” The company is evaluating PIN-5018 as both a monotherapy and in multiple combination regimens. The Phase 1 study employs a dose-escalation design to assess safety, pharmacokinetics (PK), and target engagement/pharmacodynamics (PD). Pin Therapeutics also plans to expand development into additional indications.

  • PIN-5018 Achieves Complete Response in ACC PDX Models

The company highlighted compelling preclinical data in ACC, a disease with no approved standard-of-care therapy. In two patient-derived xenograft (PDX) models, treatment with PIN-5018 resulted in a complete response (CR) in one model and marked tumor regression in the other, demonstrating robust antitumor activity and supporting clinical translation.

  • Expansion Planned into mCRPC, Colorectal Cancer, and Other Rare Tumors

Pin Therapeutics notes that CK1α plays a key biological role in resistance mechanisms that emerge during androgen receptor (AR) inhibitor therapy. Based on this insight, the company is pursuing a strategy aimed at enabling rapid entry into the first-line (1L) setting for metastatic castration-resistant prostate cancer (mCRPC) through combination therapy with an AR signaling inhibitor (ARSI). In colorectal cancer, the company is advancing a clinical program based on the innovative concept of “synthetic activation of WNT signaling.”

  • Advancing Mechanism-Based Precision Oncology

Pin Therapeutics emphasized its commitment to mechanism-based precision oncology across its entire pipeline by applying sophisticated biological mechanisms. Ongoing initiatives include mode-of-action studies, integrated PK/PD analysis, and biomarker development to identify the most appropriate patient populations for each indication.

“Our goal is to leverage our innovative degradation modality and novel biological frameworks to provide meaningful therapeutic options for cancer patients with limited or no existing treatments,” Pin Therapeutics CEO Hyunsun Jo said. “We look forward to demonstrating the clinical value of PIN-5018 across multiple tumor types.”

1...1,7191,7201,721...6,464Page 1,720 of 6,464